Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta.
chronic hepatitis B
chronic hepatitis delta
serum fibrosis markers
transient elastography
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
30
12
2022
received:
12
06
2022
accepted:
03
01
2023
medline:
20
4
2023
pubmed:
19
1
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
Assessment of liver fibrosis by non-invasive means is clinically important. Studies in chronic hepatitis delta (CHD) are scarce. We evaluated the performance of eight serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), age-platelet index (API), AST-to platelet-ratio-index (APRI), Goteborg University Cirrhosis Index (GUCI), Lok index, cirrhosis discriminant score (CDS) and Hui score] in CHD and chronic hepatitis B (CHB). Liver stiffness was assessed by transient elastography (TE) in CHD. The ability of fibrosis markers to detect significant fibrosis and cirrhosis were evaluated in 202 CHB and 108 CHD patients using published and new cut-offs through receiver operating characteristics (ROC) analysis. The latter was also applied to obtain cut-offs for TE. APRI, Fib-4, API and Hui score were assessed for significant fibrosis, and APRI, GUCI, Lok index, CDS and AAR for cirrhosis determination. Fibrosis markers displayed weak performance in CHB for significant fibrosis with area under ROC (AUROC) curves between 0.62 and 0.71. They did slightly better for CHD. TE displayed an AUROC of 0.92 and performed better than serum fibrosis markers (p < 0.05 for fibrosis markers). For cirrhosis determination, CDS and Lok Index displayed an AUROC of 088 and 0.89 in CHB and GUCI, Lok index and APRI displayed AUROCs around 0.90 in CHD. TE displayed the best AUROC (0.95). Hence TE is superior to serum fibrosis markers for diagnosing significant liver fibrosis and cirrhosis. GUCI, Lok index and APRI displayed a reasonable performance in CHD, which needs further confirmation.
Substances chimiques
Alanine Transaminase
EC 2.6.1.2
Biomarkers
0
Aspartate Aminotransferases
EC 2.6.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-416Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Takyar V, Etzion O, Heller T, et al. Complications of percutaneous liver biopsy with the Klatskin needles: a 36-year single-center experience. Aliment Pharmacol Ther. 2017;45:744-753.
Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344:495-500.
Lutterkort G, Wranke A, Yurdaydin C, et al. Non-invasive fibrosis score for hepatitis delta. Liver Int. 2016;37:196-204.
Takyar V, Surana P, Kleiner DE, et al. Non-invasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017;45:127-138.
Da BL, Surana P, Takvar V, et al. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat. 2020;27:428-436.
Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237-244.
Yurdaydin C. New treatment options for delta virus: is a cure in sight? J Viral Hepat. 2019;26:618-626.
Yurdaydin C, Keskin O, Kalkan Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: the LOWR HDV - 1 study. Hepatology. 2018;67:1224-1236.
Willilams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988;95:734-739.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.
Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR cooperative study groups. J Viral Hepat. 1997;4:199-208.
Hui AY, Chan HL, Wong VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol. 2005;100:616-623.
Bonacini M, Hadi G, Govindarajan S, Lindsay KL. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1997;92:1302-1304.
Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005;42:282-292.
Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol. 2005;40:867-872.
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-699.
Rosenberg WMC, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704-1713.
Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PMM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129-1135.
Hanley JA, McNeil BJ. Method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
Bozdayi AM, Aslan N, Bozdayi G, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004;149:2115-2129.
Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24:3-20.
Loomis AK, Kabadi S, Preiss D, et al. Body mass index and risk of nonalcoholic fatty liver disease: two electronic health record prospective studies. J Clin Endocrinol Metab. 2016;101:945-952.
Hourigan LE, Macdonald GA, Purdie DA, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-1219.
Jin W, Lin Z, Xin Y, Jiang X, Dong Q, Xuan S. Diagnostic accuracy of the aspartate aminotransferase-to- platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol. 2012;12:14.
Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of the aspartate aminotransferase to platelet ratio index and fibrosis 4 index for detecting liver fibrosis in adults with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61:292-302.
Parikh P, Ryan JD, Tsochatzis EA. Fibrosis assessment in patients with chronic hepatitis B virus infection. Ann Transl Med. 2017;5(3):40.
EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2016;63:237-264.
Chan HLY, Wong GLH, Choi PCL, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (FibroScan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36-44.
Heidrich B, Serrano BC, Idilman R, et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int. 2012;32:1415-1425.
Seven G, Karatayli SC, Köse SK, et al. Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turk J Gastroenterol. 2011;22:305-314.
Yurdaydin C, Keskin O, Kalkan C, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease. J Infect Dis. 2018;217:1184-1192.
Wranke A, Heidrich B, Svenja A, et al. Ten-year follow-up of a randomized clinical trial in chronic hepatitis delta. J Viral Hepat. 2020;27:1359-1368.
Rosina T, Conoscitore P, Cuppone R, et al. Changing pattern of chronic hepatitis D in southern Europe. Gastroenterology. 1999;117:161-166.
Palom A, Sopena S, Riverio-Barciela M, et al. One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease. Aliment Pharmacol Ther. 2021;54:462-469.
Gençdal G, Zeybel M, Yurdaydin C. Natural history of hepatitis delta virus-induced liver disease: less severe today but still needs attention. Aliment Pharmacol Ther. 2021;54:519-520.
Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314.
Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013-1021.
Ma J, Jiang Y, Gong G. Evaluation of seven non-invasive models in staging liver fibrosis in patients with chronic hepatitis B virus infection. Eur J Gastroenterol Hepatol. 2013;25:428-434.
Houot M, Ngo Y, Munteanu M, Marque S, Poynard T. Systemic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther. 2016;43:16-29.
Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322-331.
Da BL, Surana P, Kleiner DE, et al. The delta-4 fibrosis score (D4FS): a novel fibrosis score in chronic hepatitis D. Antiviral Res. 2020;174:104691.